Yanan Zhu Analyst PerformanceDirector at Wells Fargo & CompanyYanan Zhu is a stock analyst at Wells Fargo & Company in the medical sector, covering 25 publicly traded companies. Over the past year, Yanan Zhu has issued 46 stock ratings, including strong buy, buy, and hold recommendations. While full access to Yanan Zhu's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Yanan Zhu's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings62 Last 4 YearsBuy Recommendations73.77% 45 Buy RatingsCompanies Covered25 Unique Companies Ratings Distribution61RatingsDistribution of strong buy, buy, hold, and sell ratings by Yanan Zhu.RatingPercentageCount Strong Buy3.3%2 ratings Buy70.5%43 ratings Hold26.2%16 ratings Sell0.0%0 ratingsOut of 61 total stock ratings issued by Yanan Zhu at Wells Fargo & Company, the majority (70.5%) have been Buy recommendations, followed by 26.2% Hold and 3.3% Strong Buy.Best & Worst CallsBest Call0000.0%BEAMMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%SRPTApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ25 companiesYanan Zhu, an analyst at Wells Fargo & Company, currently covers 25 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical25 companies100.0%Yanan Zhu of Wells Fargo & Company specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE18 companies72.0%MED - DRUGS5 companies20.0%MED - GENERIC DRG1 company4.0%PHARMACEUTICAL PREPARATIONS1 company4.0% Yanan Zhu's Ratings History at Wells Fargo & Company Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsMGXMetagenomi5/12/2026Lower Price Target$1.34$9.00Overweight$0.0000.00% ROIENGNenGene5/8/2026Reiterated Rating$1.72$2.00Equal Weight$0.0000.00% ROIENGNenGene5/8/2026Downgrade$1.50$2.00Equal Weight$0.0000.00% ROICYTKCytokinetics5/7/2026Boost Price Target$74.64$105.00Overweight$0.0000.00% ROIONCBeOne Medicines5/4/2026Initiated Coverage$293.86$400.00Overweight$0.0000.00% ROIONCBeOne Medicines5/4/2026Upgrade$297.49Strong-Buy$0.0000.00% ROISYRESpyre Therapeutics4/14/2026Boost Price Target$63.27$90.00Overweight$0.0000.00% ROICYTKCytokinetics4/10/2026Initiated Coverage$64.59$95.00Overweight$0.0000.00% ROIRNAAvidity Biosciences3/11/2026Initiated Coverage$14.67Overweight$0.0000.00% ROIRNAAvidity Biosciences3/10/2026Upgrade$14.57Strong-Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. QUREuniQure3/9/2026Upgrade$14.27$60.00Overweight$0.0000.00% ROIQUREuniQure3/3/2026Reiterated Rating$10.50$15.00Equal Weight$0.0000.00% ROINTLAIntellia Therapeutics3/3/2026Boost Price Target$14.07$15.00Equal Weight$0.0000.00% ROIQUREuniQure3/2/2026Downgrade$9.03$15.00Equal Weight$0.0000.00% ROISRPTSarepta Therapeutics2/27/2026Lower Price Target$16.66$38.00Overweight$0.0000.00% ROIACLXArcellx2/23/2026Downgrade$64.11$115.00Equal Weight$0.0000.00% ROISYRESpyre Therapeutics2/20/2026Boost Price Target$42.03$50.00Overweight$0.0000.00% ROIRAPTRapt Therapeutics1/20/2026Downgrade$57.55$58.00Equal Weight$0.0000.00% ROITSHATaysha Gene Therapies1/5/2026Boost Price Target$5.25$11.00Overweight$0.0000.00% ROIIONSIonis Pharmaceuticals1/5/2026Boost Price Target$79.67$100.00Overweight$0.0000.00% ROIQUREuniQure11/12/2025Lower Price Target$30.26$60.00Overweight$0.0000.00% ROINTLAIntellia Therapeutics11/7/2025Lower Price Target$9.19$12.00Equal Weight$0.0000.00% ROISRPTSarepta Therapeutics11/5/2025Lower Price Target$18.35$45.00Overweight$0.0000.00% ROIRAPTRapt Therapeutics11/3/2025Set Price Target$30.21$72.00Overweight$0.0000.00% ROINTLAIntellia Therapeutics10/28/2025Reiterated Rating$13.95$17.00Equal Weight$0.0000.00% ROINTLAIntellia Therapeutics10/27/2025Downgrade$13.96Hold$0.0000.00% ROIARCTArcturus Therapeutics10/23/2025Lower Price Target$11.08$20.00Overweight$0.0000.00% ROIRAPTRapt Therapeutics10/21/2025Reiterated Rating$33.67$48.00Overweight$0.0000.00% ROICRSPCRISPR Therapeutics10/13/2025Set Price Target$73.07$75.00$0.0000.00% ROIQUREuniQure10/2/2025Boost Price Target$54.99$80.00Overweight$0.0000.00% ROIQUREuniQure9/25/2025Boost Price Target$48.60$65.00Overweight$0.0000.00% ROIEDITEditas Medicine9/3/2025Boost Price Target$2.50$4.00Equal Weight$0.0000.00% ROINAMSNewAmsterdam Pharma8/25/2025Initiated Coverage$25.00$45.00Overweight$0.0000.00% ROIIONSIonis Pharmaceuticals8/22/2025Boost Price Target$43.24$82.00Overweight$0.0000.00% ROIMGXMetagenomi8/14/2025Lower Price Target$1.90$12.00Overweight$0.0000.00% ROITSHATaysha Gene Therapies8/13/2025Boost Price Target$2.91$8.00Overweight$0.0000.00% ROIFATEFate Therapeutics8/13/2025Lower Price Target$0.94$2.50Equal Weight$0.0000.00% ROIAUTLAutolus Therapeutics8/13/2025Lower Price Target$2.15$5.00Overweight$0.0000.00% ROIARCTArcturus Therapeutics8/12/2025Lower Price Target$11.39$42.00Overweight$0.0000.00% ROIRAPTRapt Therapeutics8/8/2025Reiterated Rating$10.25$38.00Overweight$0.0000.00% ROIGoldman Sachs just told you what to buy (most people missed it) (Ad)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.See the stock positioned to solve AI's biggest power crisisNTLAIntellia Therapeutics8/8/2025Reiterated Rating$11.46$45.00Overweight$0.0000.00% ROIIOVAIovance Biotherapeutics8/8/2025Lower Price Target$2.27$14.00Overweight$0.0000.00% ROIRNAAvidity Biosciences8/8/2025Boost Price Target$46.57$75.00Overweight$0.0000.00% ROISRPTSarepta Therapeutics8/7/2025Boost Price Target$17.56$50.00Overweight$0.0000.00% ROISRPTSarepta Therapeutics7/24/2025Lower Price Target$12.33$48.00Overweight$0.0000.00% ROISRPTSarepta Therapeutics7/17/2025Lower Price Target$21.89$65.00Overweight$0.0000.00% ROIMGXMetagenomi5/14/2025Reiterated Rating$1.49$16.00Overweight$0.0000.00% ROIARCTArcturus Therapeutics5/14/2025Lower Price Target$11.11$45.00Overweight$0.0000.00% ROIADAPAdaptimmune Therapeutics5/14/2025Lower Price Target$0.28$1.00Equal Weight$0.0000.00% ROIAFMDAffimed5/13/2025Reiterated Rating$0.13$0.10Equal Weight$0.0000.00% ROIBEAMBeam Therapeutics5/7/2025Lower Price Target$15.78$70.00Overweight$00.0000.00% ROISRPTSarepta Therapeutics4/11/2025Initiated Coverage$50.31$115.00Overweight$00.0000.00% ROIRGLSRegulus Therapeutics3/27/2025Upgrade$1.73$6.00Overweight$0.0000.00% ROIADAPAdaptimmune Therapeutics3/21/2025Lower Price Target$0.29$1.50Equal Weight$0.0000.00% ROIAUTLAutolus Therapeutics3/21/2025Lower Price Target$1.72$6.00Overweight$0.0000.00% ROIMGXMetagenomi3/18/2025Lower Price Target$1.88$20.00Overweight$0.0000.00% ROIVYGRVoyager Therapeutics3/12/2025Set Price Target$3.68$10.00Overweight$0.0000.00% ROIARCTArcturus Therapeutics3/7/2025Lower Price Target$14.73$50.00Overweight$0.0000.00% ROIFATEFate Therapeutics3/6/2025Lower Price Target$0.91$4.00Equal Weight$0.0000.00% ROINTLAIntellia Therapeutics2/28/2025Lower Price Target$9.95$50.00Overweight$00.0000.00% ROINTLAIntellia Therapeutics1/10/2025Lower Price Target$11.50$60.00Overweight$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialDeutsche Bank AktiengesellschaftBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
